Hypotensive Action and Side Effects of Clonidine-Chlorthalidone and Methyla
dopa-Chlorthalidone in Treatment of Hypertension

A. AMERY,* M.D.; M. VERSTRAETE,† M.D.; H. BOSSAERT,‡§ M.D.; G. VERSTREKEN,† M.D.


Summary: In an open, randomized, cross-over study the hypotensive action and side effects of clonidine-chlorthalidone and methyla
dopa-chlorthalidone combinations were compared. The diastolic morning blood
depressor could be reduced to 95 mm. Hg or below in
significantly more patients with clonidine than with methyla
dopa. Side effects, however, were more commonly
countered during the clonidine than during the methyla
dopa phase.

Introduction

It has been shown conclusively that clonidine produces a sub-
stantial lowering of blood pressure during prolonged oral
treatment of hypertensive patients. The exact place of this
new drug among hypotensive agents is as yet unspecified. It
seemed to us that a comparative study of clonidine and one or
more established hypotensive agents would be useful, with
special attention to their respective hypotensive actions and
the nature and frequency of side effects during prolonged oral
administration in ambulant patients. This paper reports an
open, randomized, cross-over study comparing clonidine and
methyla
dopa.

Chlorthalidone was associated with both drugs since a
diuretic enhances the hypotensive effect of methyla
dopa (Wilson et al., 1963; Colwil et al., 1964; Smith et al., 1966)
and clonidine (Jungling, 1968; Onesti et al., 1969).

Patients and Methods

Selection of Patients

Before admission to the study patients had to fulfil all of the
following positive and none of the negative criteria.

Positive Criteria.—A persistently raised diastolic blood pressure
(measured in the hospital, in the outpatient clinic, or by the house
physician) of 110 mm. Hg or more. A persistent diastolic blood
pressure of 90 mm. Hg or more during diuretic treatment (50 mg.
of chlorthalidone daily). The patient had to be willing to collaborate
and able to record his own blood pressure at home four times each
day: recumbent before rising in the morning, standing within five
minutes after rising in the morning, standing in the evening before
going to bed, and recumbent in the evening after five minutes' rest
in bed.

Negative Criteria.—Presence of grade IV retinopathy (Keith
Wagener) at any time before admission to the study. Severe renal
insufficiency: two subsequent determinations of a serum creatinine
of 4 mg./100 ml. or more. Hypertension secondary to Conn's or
Cushing's syndrome or to a pheochromocytoma. No contraindia-
tions to thiazide treatment—that is, serum uric acid level of
10 mg./100 ml. or more, with or without diuretic; symptoms of
gout before or during diuretic treatment; severe diabetes mellitus
requiring 40 units of insulin or more; and digitalis administration.

Preliminary Investigation

All patients underwent investigation, including a history;
physical examination including fundoscopy; chest x-ray exam-
ination; electrocardiogram; creatinine, electrolytes, and uric
acid in serum; blood glucose; 24-hour creatinine clearance;
intravenous pyelogram; and urine examination for glucose
and protein and microscopy of the sediment. Other tests,
including urinary catecholamines, arteriography of the renal
arteries, etc., were performed when indicated.

Therapeutic Regimen

Throughout the study all patients received 50 mg. of
chlorothalidone daily. All other antihypertensive agents were
interrupted at least one month before admission to the study.
The decision to admit a patient to the study was made after
repeated visits to the hypertension clinic when the results of the
tests mentioned above were available and when it was
certified that the patient was able to take correctly his blood
pressure at home.

Patients admitted on an even day began with methyla
dopa (250 mg. per tablet). It was planned to adjust the number of
tables weekly until the recumbent morning diastolic blood
pressure, recorded by the patient, was 90 mm. Hg or less, or
until a maximum of 10 tablets a day was reached. Patients
were seen at monthly intervals at the hypertension clinic,
where the number of tablets was altered if required. The
patient was transferred to clonidine (0.3 mg. per tablet)
treatment if sufficient blood-pressure control was obtained
during the previous month or when, notwithstanding the
daily intake of 10 × 250 mg. tablets of methyla
dopa, the blood
pressure was not sufficiently controlled. The same decision
was taken if the blood pressure remained too high and fur-
ther increase of drug intake seemed to be impossible because
of side effects. During the clonidine phase the daily intake
was also increased to a maximum of 10 tablets a day. Patients
admitted on an uneven day started with clonidine and were
transferred to methyla
dopa, the same criteria being used.

The shortest time the patients were on one drug was two
months; most of them took each drug during three months,
and the longest phase on one drug was four months. The
tables were taken three times a day—on rising in the morn-
ing after blood-pressure measurement, at noon, and before
sleeping at night after blood-pressure measurement. If fewer
than three tablets were taken the noon and morning doses
were omitted; if three or more tablets were taken they were
divided into three doses, the evening dose being equal to or
greater than the others.

Controls

The patients measured their blood pressure at home four
times a day and noted the results on a special data sheet,
which was handed to the doctor at each outpatient visit. The
mean and standard deviations of the last 10 days were
calculated and used in the figures given in the Tables.

During each visit to the hypertension clinic three points
were checked. (1) The patients were questioned on the nature
and number of tablets, and by use of a questionnaire the
frequency and importance of side effects were recorded (see
Table VIII). (2) Blood-pressure readings taken in recumbent
and standing positions by the patient with his own egotes.

* Supplied by Bayer as Presivon.
† Professor of Medicine; Head of the Section of Blood Coagulation.
‡ Investigator of the Belgium Research Council.
§ University of Louvain, Belgium.
apparatus were compared with data obtained by the doctor using a mercury-calibrated blood-pressure apparatus. The patients were instructed to use phase 5 of the Korotkoff sounds as the diastolic pressure. (3) Electrolytes, creatinine, and uric acid in the serum were determined.

Results

Patients Admitted to the Study

Data showing the aetiology and severity of the hypertension in the 41 patients are given in Table I. Drugs other than chlorothalidone, clonidine, or methyldopa were interrupted except in one patient who was maintained on insulin (24 units daily). The 24-hour proteinuria was less than 0.5 g. in 40 patients; the patient with chronic glomerulonephritis excreted 3.5 g. of protein a day. No patient had congestive heart failure on admission and none was taking digitalis.

Dose of Drugs Eventually Taken

The dose of the drugs taken by the patients averaged 1.23 mg. of clonidine a day and 1.75 g. of methyldopa a day. Therefore in this group 1.75 g. of methyldopa (7 tablets of 250 mg.) corresponded to 1.23 mg. of clonidine (4-1 tablets of 0.3 mg.) or 0.7 mg. of clonidine corresponded to 1 g. of methyldopa. The equivalence in individual cases varied from 0.12 to 1.5 mg. of clonidine per g. of methyldopa.

There were three reasons for not further increasing the drug dosage above the amounts mentioned: sufficient blood-pressure control (diastolic recumbent morning pressure <95 mm. Hg) in 25 patients on methyldopa and 34 on clonidine, side effects in 5 patients on methyldopa and 3 on clonidine, and in 11 patients on methyldopa and 4 on clonidine because the required dose would have exceeded the set maximal dosage of 10 tablets a day.

Blood-pressure Response

Blood pressure at End of Each Phase.—The mean and standard deviation calculated from the average blood pressures obtained for each patient in different conditions during the last 10 days of each phase are given in Table II.

Diastolic Pressure taken at Home in the Morning.—The number of patients whose blood pressure was 95 mm. Hg or lower when measured at home in the morning in the recumbent position was significantly (0.05 > P > 0.002) higher at the end of the clonidine phase than at the end of the methyldopa administration (Table III). The same trend was also noted when the pressure was measured at other times of the day, in the standing position, or when the systolic values were taken into account. One possible explanation for this difference could be that several patients had been treated with methyldopa before entering the study and had developed some resistance to the drug. Therefore analogous calculations made with the chi² two-tailed test were repeated on the restricted group of patients who did not receive either methyldopa or clonidine before admission to the study; a significant (0.02 > P > 0.01) difference was still observed (Table IV).

Difference Between Morning and Evening Blood pressures.—A lower blood pressure in the morning has been often observed in hypertensive patients both when untreated and when receiving therapy, especially with guanethidine. The differences in recumbent morning and evening systolic and diastolic readings during methyldopa and clonidine treatment are shown in Table V. During both the methyldopa and the clonidine therapy the pressure tends to be higher in the evening. This difference reaches a level of significance during clonidine therapy for the systolic (0.05 > P > 0.001) and diastolic pressure (P < 0.001) and also during methyldopa therapy for the systolic (P < 0.001) and diastolic (0.05 > P > 0.001) pressure. The rise in the recumbent systolic pressure from morning to evening tended to be more pronounced during methyldopa (7.25/3.04 mm. Hg) therapy than during clonidine treatment (6.99/4.42 mm. Hg); this was, however, not significant (P > 0.1). The same tendency can be seen for

<table>
<thead>
<tr>
<th>Conditions of Blood Pressure Measurement</th>
<th>Blood Pressure (mm. Hg) When Measured</th>
<th>No. of Patients at End of Each Phase</th>
<th>Methyldopa</th>
<th>Clonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning recumbent</td>
<td>140 ± 17-1</td>
<td>34</td>
<td>17</td>
<td>19</td>
</tr>
<tr>
<td>Morning standing</td>
<td>90 ± 11-8</td>
<td>85 ± 9-1</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Evening standing</td>
<td>94 ± 11-2</td>
<td>88 ± 9-0</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Evening recumbent</td>
<td>97 ± 11-7</td>
<td>91 ± 8-5</td>
<td>12</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood Pressure (mm. Hg) of Recumbent Morning at Home</th>
<th>No. of Patients at End of Each Phase</th>
<th>Methyldopa</th>
<th>Clonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 95</td>
<td>16</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>&lt; 95</td>
<td>25</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>41</td>
<td>41</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Differences Between Systolic (mm. Hg)</th>
<th>Methyldopa X ± S.D.</th>
<th>Clonidine X ± S.D.</th>
<th>P between Methyldopa and Clonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.25 ± 8.93</td>
<td>&lt; 0.001</td>
<td>6.99 ± 13</td>
<td>0.05 &gt; P &gt; 0.001</td>
</tr>
</tbody>
</table>

TABLE II.—Blood Pressure at End of Each Phase

TABLE III.—Response of the Recumbent Morning Home Diastolic Blood Pressure to Both Drugs

TABLE IV.—Response of Recumbent Morning Blood Pressure to Both Drugs in Patients Not Previously Treated With One of Them

TABLE V.—Differences Between Recumbent Evening Minus Recumbent Morning Blood Pressure
the diastolic pressure. The differences between standing morning and standing evening systolic and diastolic pressure during methyldopa and clonidine treatment are shown in Table VI. The interpretation of the recumbent blood pressure also seems to be valid here.

**Difference between Standing and Recumbent Blood Pressure.** Differences in recumbent and standing blood pressure during anti-hypertensive therapy, especially with blockers of the adrenergic neurousmuscular transmission, can be a troublesome side effect and are most pronounced in the morning. These differences during clonidine and methyldopa administration of the lying and standing blood pressure are given in Table VII; they were significant only for the diastolic blood pressure. Though the fall on rising tends to be smaller during the clonidine than during the methyldopa treatment the difference was not significant (P > 0.05).

**Side Effects**

At the end of the clonidine and methyldopa phase each of the 41 patients was asked a series of set questions (Table VIII). Dryness of the mouth, constipation, and drowsiness were significantly more frequent (P < 0.001) during clonidine treatment. There was a tendency to more frequent headaches in the methyldopa phase. If, however, one does not consider the total number of patients (41) but only those in whom the blood pressure was sufficiently controlled with both drugs (18) the frequency of headaches (17%) was the same with both drugs.

In some cases because of side effects the drug dosage could not be increased enough to bring the blood pressure to nor-

**TABLE VI.** Differences between Standing Evening Minus Standing Morning Blood Pressure

<table>
<thead>
<tr>
<th></th>
<th>Methyldopa</th>
<th>Clonidine</th>
<th>P between Methyldopa and Clonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic B.P.</td>
<td>X ± S.D.</td>
<td>X ± S.D.</td>
<td></td>
</tr>
<tr>
<td>Differences</td>
<td>8.99 ± 11.33</td>
<td>6.93 ± 12.09</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>P Value for these differences</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE VII.** Differences between Recumbent Evening Minus Standing Blood Pressure in the Morning

<table>
<thead>
<tr>
<th></th>
<th>Methyldopa</th>
<th>Clonidine</th>
<th>P between Methyldopa and Clonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic B.P.</td>
<td>X ± S.D.</td>
<td>X ± S.D.</td>
<td></td>
</tr>
<tr>
<td>Differences</td>
<td>5.1 ± 9.99</td>
<td>2.81 ± 12.95</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>P Value for these differences</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE VIII.** Side Effects during Clonidine and Methyldopa Treatment of 41 Cases

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Clonidine</th>
<th>Methyldopa</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dryness of the mouth</td>
<td>24</td>
<td>58</td>
<td>5</td>
</tr>
<tr>
<td>Constipation</td>
<td>11</td>
<td>27</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Parasthesia</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Impotence</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Tiredness</td>
<td>4</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>23</td>
<td>56</td>
<td>4</td>
</tr>
<tr>
<td>Headache</td>
<td>7</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Epigastric complaints</td>
<td>1</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Heart palpitation</td>
<td>0</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Raynaud's phenomenon</td>
<td>2</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Micturition difficult</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

This occurred in three patients during the clonidine phase and in five during methyldopa administration. Sedation in one patient and vomiting in another were severe enough to necessitate interruption of clonidine therapy. During administration of methyldopa side effects were never severe enough to make interruption of treatment necessary.

**Discussion**

**Present Data**

The study was neither a single nor a double-blind study; the tablets used were similar in taste, colour, and shape to the commercially available tablets of Presinol and Catapres respectively. In most instances these tablets were unknown to the patients before the start of the study; they were told that the drugs were different. Furthermore, no special procedures were used to ensure that the patients were in fact taking the tablets given to them on each visit to the hypertension clinic.

Our results showed that in a significantly greater number of patients the diastolic morning blood pressure could be reduced to 95 mm. Hg or less with clonidine-chlorthalidone than with methyldopa-chlorthalidone. Since this difference was also seen in the patient not treated previously with one of these drugs, the possibility that some of the patients had developed resistance to one of the drugs before the study was excluded. On average each treatment phase (clonidine or methyldopa) was for about three months, as the number of pills was usually increased rather slowly and the patients were maintained on the individually maximum dose for one month. From the present data we do not know if the observed difference would also hold during longer periods of treatment. Side effects, however, were more commonly encountered during the chlorthalidone-clonidine phase than during the chlorthalidone-methyldopa phase, and more patients preferred the latter to the former combination of drugs.

When hypotensive treatment with clonidine or methyldopa is considered we would prefer, from these results, to start with the chlorthalidone-methyldopa combination, except when rapid blood-pressure control or some degree of sedation is desirable. If sufficient blood-pressure control cannot be achieved by the chlorthalidone-methyldopa treatment we would then use the other combination. The latter could be contraindicated when excessive sedation could become dangerous—for instance, in car drivers. On the other hand, if a patient is not controlled by a chlorthalidone-clonidine regimen it is unlikely that he will be controlled under a chlorthalidone-methyldopa regimen.

**Comparison with Published Data**

Jungling (1968), in the short-term treatment of four patients, administered 0.075 mg. of clonidine three times during six days and then 3.75 mg. of methyldopa three times during six days; the blood pressure at the end of each period was respectively 158/108 and 158/100. In four other patients the sequence was reversed and the blood pressure at the end of the methyldopa period was 183/99 and at the end of the clonidine period 177/99 mm. Hg. Side effects are not mentioned in this group.

So far as we know no controlled (open, single, or double-blind) study comparing methyldopa and clonidine in the treatment of hypertension over a longer period of time has been published. Several groups have, however, transferred patients previously treated with methyldopa to clonidine treatment. In a preliminary report Seedat et al. (1969) described 30 patients treated in this way, stating that "effec-
tive" control of blood pressure was achieved with both drugs. Nevertheless, clonidine caused side effects in 23 and methyldopa in only 11 of the 30 patients. The nature of the side effects was similar to those described in our study.
al. (1969) mentioned that a dose of 0.4 to 1.2 g. of clonidine is equivalent to 1.5 to 2.0 g. of methyldopa. These data and our present findings agree on the following points: that 0.7 mg. of clonidine corresponds to about 1 g. of methyldopa, that blood-pressure control can be achieved at least as well with clonidine as with methyldopa, and that side effects are more frequent during clonidine than during methyldopa treatment.

The present study compares only clonidine-chlordiazepoxide to methyldopa-chlordiazepoxide. To specify the exact place of clonidine of prolonged treatment of hypertension a comparative study of clonidine and other antihypertensive agents is desirable.

**References**


**Serum Fibrin/Fibrinogen Degradation Products Associated with Postoperative Pulmonary Embolus and Venous Thrombosis**

C. V. RUCKLEY,* CH.M., F.R.C.S.ED.; P. C. DAS† M.B., B.S., PH.D.; A. G. LEITCH‡ B.SC.


A. T. REDPATH|| B.SC., PH.D., A.INST.P.; P. SCOTT¶§ J. D. CASH,** PH.D., F.R.C.P.ED.

*Senior Surgical Registrar, University Department of Clinical Surgery and General Surgical Unit, Western General Hospital, Edinburgh.
†Registrar, South-East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh.
‡Medical Student, Western General Hospital, Edinburgh.
§Medical Physicist, Western General Hospital, Edinburgh.
||Laboratory Assistant, South-East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh.
¶¶Deputy Director, South-East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh.

Summary: A total of 76 “high-risk” surgical patients were studied for evidence of venous thromboembolic disease. Episodes of deep vein thrombosis and of pulmonary embolism were related to changes in blood levels of fibrin degradation products (F.D.P.). When diagnosed either by ordinary clinical means or by venography and isotope scanning significantly raised F.D.P. levels were found in all cases. Serum F.D.P. estimations are unlikely to help in detecting deep vein thrombosis, but may prove valuable in diagnosing pulmonary embolism.

**Introduction**

Accurate diagnosis is essential to the evaluation of treatment. nowhere is this better illustrated than in assessing a widening range of therapy for venous thromboembolic disease. It is now universally recognized that deep vein thrombosis is not reliably detected by clinical examination. Robertson (1968) concluded that the frequency with which venous thrombosis has been diagnosed before death varies between 5 and 26%. This has been confirmed by studies where the diagnosis could be substantiated by necropsy (Gibbs, 1957; Sevitt and Gallagher, 1961; Freiman et al., 1965), isotope studies (Atkins and Hawkins, 1968; Negus et al., 1968), or the use of ultrasonics (Strandness et al., 1967; Sigel et al., 1968).

Pulmonary embolism too is seriously underdiagnosed, and possibly a positive diagnosis before death is made in only 30% to 50% of cases (Prettin, 1936; Smith et al., 1965). Moreover, patients in whom minor or silent episodes, or both, are left untreated may die from further embolism or extension of thrombi from the original embolus—sequelae which may be prevented by adequate systemic treatment with heparin (Thomas, 1965). Morrell et al. (1963) calculated that between 1952 and 1961 at least one preventable death occurred every fortnight in the two major hospitals in Oxford. More recently, in a careful study of 263 right lungs, the same group found evidence of pulmonary emboli in 51.7% (Morrell and Dunnill, 1968).

Newer methods of diagnosing embolism include pulmonary angiography (Cooley, 1964; Littmann, 1965; Stein et al., 1967), isotope scanning (Wagner et al., 1964; Sabiston and Wolfe, 1967), and ultrasonics (Joyner et al., 1967). These advanced diagnostic techniques demand, in varying measure, considerable expertise, expense, and time. In angiography and isotope work there is some discomfort or risk to the patient, or both. None is ideal as a screening method for routine clinical use, and new and simpler diagnostic aids are urgently required.

During the proteolysis of fibrinogen and fibrin by the fibrinolytic enzyme plasmin several fragments are released which are unclottable and incapable of further digestion (Nussenzweig and Seligmann, 1960; Alkjaersig et al., 1962). Two of these fibrinogen/fibrin degradation products (F.D.P.), the so-called D and E fragments, have an antigenic determinant which is related to the parent fibrinogen. This property has made it possible to adapt the tanned red cell haemagglutination inhibition immunoassay of Boyden (1951) to estimate serum F.D.P. quantitatively (Murakami, 1965; Merskey et al., 1966) and provide some information on the level of actual in-vivo fibrin deposition and lysis in those clinical states not associated with fibrinogenolysis. This technique is so sensitive that abnormally high values of serum F.D.P. can be detected before there is clear collateral evidence of a depletion of platelets, fibrinogen, and other coagulation factors. Thus immunoassay may be used to show occult intravascular coagulation and fibrinolysis, thereby offering a new approach to the diagnosis of suspected and occult venous thrombosis or pulmonary embolism, or both.

Earlier investigations in this laboratory ascertained the normal range of serum F.D.P. in adults (Das et al., 1967) and in infants and children (Utley et al., 1969), and further pilot studies in patients after acute myocardial infarction and following surgical operations suggested that the measurement of these polypeptides may be useful in the diagnosis of acute